AIM: Imatinib is a tyrosine kinase inhibitor that has revolutionized the treatment of chronic myeloid leukemia (CML). Despite its efficacy, about a third of patients discontinue the treatment due to therapy failure or intolerance. The rational identification of patients less likely to respond to imatinib would be of paramount clinical relevance. We have shown that transmembrane transporter hOCT1 genotyping predicts imatinib activity. In parallel, Polycomb group genes (PcGs) are epigenetic repressors implicated in CML progression and in therapy resistance. PATIENTS & METHODS: We measured the expression of eight PcGs in paired pre- and post-imatinib bone marrow samples from 30 CML patients. RESULTS: BMI1, PHC3, CBX6 and CBX7 expression was significantly increased during imatinib treatment. Post-treatment levels of CBX6 and CBX7 predicted 3-month response rate. Measurement of post-treatment BMI1 levels improved the predictive power of hOCT1 genotyping. CONCLUSION: These results suggest that the expression levels of PcGs might be useful for a more accurate risk stratification of CML patients.
AIM: Imatinib is a tyrosine kinase inhibitor that has revolutionized the treatment of chronic myeloid leukemia (CML). Despite its efficacy, about a third of patients discontinue the treatment due to therapy failure or intolerance. The rational identification of patients less likely to respond to imatinib would be of paramount clinical relevance. We have shown that transmembrane transporter hOCT1 genotyping predicts imatinib activity. In parallel, Polycomb group genes (PcGs) are epigenetic repressors implicated in CML progression and in therapy resistance. PATIENTS & METHODS: We measured the expression of eight PcGs in paired pre- and post-imatinib bone marrow samples from 30 CML patients. RESULTS: BMI1, PHC3, CBX6 and CBX7 expression was significantly increased during imatinib treatment. Post-treatment levels of CBX6 and CBX7 predicted 3-month response rate. Measurement of post-treatment BMI1 levels improved the predictive power of hOCT1 genotyping. CONCLUSION: These results suggest that the expression levels of PcGs might be useful for a more accurate risk stratification of CML patients.
Authors: A Di Paolo; M Polillo; M Capecchi; G Cervetti; C Baratè; S Angelini; F Guerrini; G Fontanelli; R Arici; E Ciabatti; S Grassi; G Bocci; P Hrelia; R Danesi; M Petrini; S Galimberti Journal: Pharmacogenomics J Date: 2014-03-04 Impact factor: 3.550
Authors: Sebastian Francis; Claire Lucas; Steven Lane; Lihui Wang; Sarah Watmough; Katy Knight; Jo Bell; Mohammed Kaleel-Rahman; Edwin Lee; David O'Brien; Nauman M Butt; Walid Sadik; Lally De Soysa; Jim R C Seale; Rahuman Salim; Richard E Clark Journal: Leuk Res Date: 2013-04-22 Impact factor: 3.156
Authors: Carolina Nör; Zhaocheng Zhang; Kristy A Warner; Lisiane Bernardi; Fernanda Visioli; Joseph I Helman; Rafael Roesler; Jacques E Nör Journal: Neoplasia Date: 2014-02 Impact factor: 5.715
Authors: Gang Li; Charles Warden; Zhaoxia Zou; Josh Neman; Joseph S Krueger; Alisha Jain; Rahul Jandial; Mike Chen Journal: PLoS One Date: 2013-11-15 Impact factor: 3.240
Authors: Federica Loscocco; Giuseppe Visani; Sara Galimberti; Antonio Curti; Alessandro Isidori Journal: Front Oncol Date: 2019-09-24 Impact factor: 6.244
Authors: Marialuisa Polillo; Sara Galimberti; Claudia Baratè; Mario Petrini; Romano Danesi; Antonello Di Paolo Journal: Int J Mol Sci Date: 2015-09-21 Impact factor: 5.923
Authors: Sara Galimberti; Cristina Bucelli; Elena Arrigoni; Claudia Baratè; Susanna Grassi; Federica Ricci; Francesca Guerrini; Elena Ciabatti; Carmen Fava; Antonio D'Avolio; Giulia Fontanelli; Giovanna Rege Cambrin; Alessandro Isidori; Federica Loscocco; Giovanni Caocci; Marianna Greco; Monica Bocchia; Lara Aprile; Antonella Gozzini; Barbara Scappini; Daniele Cattaneo; Anna Rita Scortechini; Giorgio La Nasa; Alberto Bosi; Pietro Leoni; Romano Danesi; Giuseppe Saglio; Giuseppe Visani; Agostino Cortelezzi; Mario Petrini; Alessandra Iurlo; Antonello Di Paolo Journal: Oncotarget Date: 2017-09-30
Authors: Elena Arrigoni; Marzia Del Re; Sara Galimberti; Giuliana Restante; Eleonora Rofi; Stefania Crucitta; Claudia Baratè; Mario Petrini; Romano Danesi; Antonello Di Paolo Journal: Stem Cells Transl Med Date: 2018-02-08 Impact factor: 6.940